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Molecular  conjugate vectors may be constructed that 
accomplish high efficiency  gene transfer by the recep- 
tor-mediated endocytosis pathway. In  order to mediate 
escape from lysosomal degradation, we have incorpo- 
rated adenoviruses into the functional design of the 
conjugate. In doing so, however, we have introduced 
an additional ligand, which can bind  to receptors on 
the cell surface, undermining the potential for cell 
specific targeting. To overcome this, we have treated 
the adenovirus with a  monoclonal anti-fiber antibody, 
which renders the virus incapable of binding to its 
receptor. The result is a multi-functional molecular 
conjugate vector, which has preserved its binding spec- 
ificity while at the same time being capable of pre- 
venting lysosomal degradation of endosome-internal- 
ized conjugate-DNA complexes. This finding indicates 
that adenoviral binding is not a prerequisite for aden- 
oviral-mediated endosome disruption. 
Gene transfer can be accomplished via the receptor-me- 
diated endocytosis pathway employing molecular conjugate 
vectors (1-8). This vector system  consists of two linked  func- 
tional domains:  a DNA  binding  domain  and a ligand  domain 
that recognizes a specific cell surface receptor. When the 
ligand  domain is recognized by the  appropriate cell surface 
receptor, the conjugate-DNA  complex is  internalized by the 
receptor-mediated endocytosis pathway,  co-transporting  the 
bound DNA. One of the  potential  advantages of molecular 
conjugates is  that  this vector system possesses the  capacity 
to  target specific cells  by virtue of the  ligand  domain of the 
conjugate. Thus,  through  the choice of the  ligand,  it  is  theo- 
retically  possible to specifically target  any cell type by virtue 
of a specific cell surface receptor. In  this regard,  Wu and CO- 
workers (1, 2) have constructed an asialoglycoprotein-poly- 
cation conjugate that  has  been  shown  to specifically target 
hepatocytes  both i n  vitro and in vivo via asialoglycoprotein 
receptors  found  on  the surface of this cell type. 
Although  molecular  conjugates  possess  a  specific and effi- 
* This work  was supported by Cystic Fibrosis Foundation Shwach- 
man Award Q493. The costs of publication of this article were 
defrayed in part by the payment of page charges. This article must 
therefore be  hereby marked “advertisement” in accordance with 18 
U.S.C. Section 1734  solely to indicate this fact. 
cient internalization mechanism, the fact that they lack a 
mechanism  to accomplish  escape  from  lysosomal degradation 
after cellular internalization has limited gene transfer effi- 
ciency ( 5 ,  9). As a strategy  to  prevent  the  endosome-internal- 
ized DNA from  being retained  within  the cell vesicle (which 
would limit gene transfer efficiency), we have incorporated 
both replication-competent and -incompetent adenoviruses 
into  the  functional design of the conjugates (10-12). Adeno- 
viruses,  which  also enter cells via the  receptor-mediated  en- 
docytosis pathway, possess a specific mechanism to escape 
the cell vesicle system by mediating  disruption of the  endo- 
somes (13). When incorporated into the conjugate design, 
adenoviruses can facilitate entry of the conjugates into  the 
cytoplasm by disrupting  the ndosome, thus greatly enhancing 
overall gene transfer efficiency (10, 11). 
In  this  configuration, however, the viral  moiety functions 
in  the  capacity of both  an endosome lysis agent  and also as 
an  alternate  ligand  domain of the conjugate. Thus, since an 
additional ligand has been introduced into the conjugate 
design, the  potential for cell specific targeting may be under- 
mined. The goal of the  present  study was to selectively exploit 
the endosome lysis functions of the  adenovirus while concom- 
itantly eliminating the adenovirus as a alternate ligand. In 
order  to accomplish this, a  monoclonal antibody  to  the fiber 
protein of adenovirus serotype 5 was generated to ablate 
adenoviral binding. We have shown that when introduced 
into  the  conjugate design, antibody-coated virions retain  the 
ability to disrupt endosomes but can no longer function as 
alternate ligands. Interestingly,  the  demonstration of selective 
exploitation of adenoviral endosome lysis establishes that 
adenoviral  binding  and vesicle disruption  are  not  functionally 
linked. 
MATERIALS AND METHODS 
Cell Lines-HeLa cells were grown as monolayers in Dulbecco’s 
modified Eagle’s  medium (DMEM)’ with 4500 mg/liter glucose and 
L-glutamine (DMEM-H) supplemented with 5% fetal bovine serum 
(FBS), penicillin, and streptomycin (complete media). The cell line 
293  was  grown as a monolayer in DMEM-H supplemented with 10% 
FBS, penicillin, and streptomycin (high serum media). 
Adenovirus-Adenovirus  was propagated and purified as previously 
described (14). The adenovirus P202-Ad5 is a chimeric serotype 5 
adenovirus that contains  a Mycoplasma pneumoniae P1 protein epi- 
tope as  part of the hexon capsid protein, which  is used to immuno- 
logically link poly(L-lysine) to  the virus (10). The cell line 293 was 
used for viral propagation. After density centrifugation, purified 
virions were stored in viral preservation media (10 mM Tris,  pH 8.0, 
100 mM NaC1. 1 mdml bovine serum albumin, and 50% (v/v) 
glycerol) at -70 “c. Y .  
PreDaration of 35S-Labeled Virus-Adenovirus labeled with 135Sl 
methionine was produced in HeLa cells as described (15). Bri‘efl; 
HeLa cells were seeded in 75-cm tissue culture flasks as monolayers 
18 h before infection with adenovirus P202. To  the HeLa flasks P202- 
Ad5 (10-100 plaque-forming units/cell), diluted in  DMEM-H supple- 
mented with 2% FBS, penicillin, and streptomycin (low serum media), 
was added. The flasks were then incubated for 1 h at 37 “C, after 
which time complete media  was added. The infection was  allowed to 
proceed for 16 h, at which time the media  was  removed and replaced 
by medium containing methionine-free DMEM, 5% dialyzed fetal 
The abbreviations used are: DMEM, Dulbecco’s  modified  Eagle’s 
medium; FBS, fetal bovine serum, mAb, monoclonal antibody; PBS, 
phosphate-buffered saline; HBS, HEPES-buffered saline; hTfpL, hu- 
man transferrin-poly(L-lysine); hTfpL/AdpL,  ternary complex. 
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calf serum, penicillin, streptomycin, and 5 mCi of [35S]methionine 
(Amersham Corp.) for a 48-h period. Cells were then removed from 
the plastic surface by vigorous shaking, and  the cell suspension was 
centrifuged at  4,000 rpm for 30 min at 4 "C. The cell pellet was 
resuspended in complete media and freeze-thawed four times. The 
cell suspension was then centrifuged at 4,000 rpm for 20 min at 4 "C. 
The  supernatant was collected and centrifuged in consecutive discon- 
tinuous CsCl gradients. After two rounds of density centrifugation, 
virions were collected, diluted in viral preservation media, and stored 
at -70 "C. The specific activity was 2 X lo5 cpm/mg of labeled virus. 
Preparation of Monoclonal Anti-fiber Antibody-Purified adenovi- 
rus type 5 fiber was prepared as described (gift of Einar  Everitt) (16). 
The fiber protein was used to immunize BALB/c mice to generate 
monoclonal anti-fiber antibodies (mAbs) as previously described (17). 
The specificities of the mAbs  were verified by Western  blotting using 
purified wild type Ad5 as antigen. Selected positive hybridomas were 
cloned twice on  soft agar and used to produce ascites fluid in BALB/ 
c mice. Assays of end point cytopathic effects of adenovirus with 
purified antibody clone 7 (afiberAb#7) showed that 1 pg  of antibody 
completely neutralized 1 X 10" particles of adenovirus. 
Binding and Internalization of afiberAb#7-coated 35S-Labeled 
Virus-To measure binding of adenovirus to cell surfaces, monolayers 
of HeLa cells grown in 60-mm plates were incubated with 35S-labeled 
adenovirus (8.31 X 10" particles/plate) at 4 "C. The virus was prein- 
cubated (30 min at room temperature) with 83.1 pg  of afiberAb#7 or 
irrelevant mAb (anti-influenza neuraminidase antibody; PY203) prior 
to addition to cells. This amount of antibody represents a 10-fold 
excess of that amount required to completely neutralize adenoviral 
infection. The incubation allowed binding without cellular internali- 
zation of virions. After a 1-h incubation period, the cells were washed 
twice with ice-cold PBS. Virus adherent to  the cell membrane was 
then harvested by treating  plates with 1 ml  of 0.1 N NaOH for 5 min 
at room temperature. Quantification of adherent virions was accom- 
plished by addition of cell lysate to 4 ml of Scintiverse (Fisher 
Scientific) and analyzed by scintillation. 
To measure adenovirus internalization, HeLa cells were incubated 
with antibody-coated 35S-labeled adenoviruses, except the incubation 
was done at 37 "C. After incubation, cells were washed twice with 
PBS  and treated with 0.1 N NaOH as above. The total amount of 
virus within the cells was determined as before. 
Preparation of Molecular Conjugate-DNA Complexes-Human 
transferrin-poly(L-lysine) conjugate (hTfpL; Serva Biochemical) con- 
sists of human transferrin covalently linked to poly(L-lysine) with an 
average chain length of 300 lysine monomers. Conjugate-DNA com- 
plexes were formed by dilution of 6 pg  of plasmid DNA in 350 p1 of 
150 mM NaCI, 20 mM HEPES,  pH 7.3 (HBS) followed by addition of 
8 pg  of hTfpL diluted in 150 pl of HBS. Complexes were formed by 
incubation for 30 min at  room temperature. 
The hTfpL/AdpL conjugate contains both an adenovirus and a 
human transferrin domain. The ternary complexes (hTfpL/AdpL. 
DNA) were prepared by combining the epitope-tagged adenovirus 
P202-Ad5 (2.5 X 10" particles) with poly(L-lysine)-conjugated mono- 
clonal antibody (10) MP30lpL (1.25 pg) diluted in 250 pl of HBS. 
The mixture was incubated at room temperature for 30 min. Plasmid 
DNA (6 pg) diluted in 125 p l  of HBS was added to  the mixture and 
incubated for an additional 30 min at room temperature. In order to 
completely condense the DNA and add a human transferrin domain 
to  the complex, human transferrin-polylysine conjugates (6 pg) di- 
luted in 125 p1 of HBS were added to  the complex and incubated for 
30 min at room temperature. The reporter DNA used for experiments 
was pCMVL, a plasmid containing the Photinus pyralis luciferase 
gene under the control of the cytomegalovirus enhancer-promoter 
(18). 
Effect of afiberAb#7 on Facilitation of Molecular Conjugate-me- 
diated Gene Transfer by Free Adenovirus-In order to determine the 
effect of afiberAb#7 on facilitation of molecular conjugate-mediated 
gene transfer by free adenovirus, hTfpL.DNA complexes were pre- 
pared as described above. Adenovirus P202-Ad5 (2.5 x 10" particles) 
was incubated with 25 pg of afiberAb#7, an  irrelevant mAb (PY203), 
prior to addition to  the hTfpL.DNA complexes. The hTfpL .DNA 
or an equivalent volume of HBS for 30 min at room temperature 
complexes and antibody-treated adenoviruses were then added to 60- 
mm tissue culture plates  containing HeLa cells (80% confluent) in 1 
ml  of  low serum media that had previously been  cooled to 4 "C for 15 
min. The plates containing the complex/adenovirus/antibody mix- 
ture were returned to 4 "C and incubated for 1 h to allow for the 
complexes and free adenovirus to bind without internalizing. Imme- 
diately following incubation, the plates were washed twice with ice- 
cold low serum media to remove any unbound conjugates and free 
adenovirus. The plates were then incubated at 37 "C for 30 min 
following a 30-min gradual warm-up at room temperature. High serum 
media was then added to  the cells prior to a 16-h incubation at 37 "C. 
After this incubation, cells were harvested for analysis of luciferase 
gene expression. Cell lysates were standardized for total protein 
content and analyzed for luciferase enzyme activity. Results were 
expressed as light units per 25  pg  of total cellular protein. 
Effect of afiberAb#7 on Adenovirus-linked Molecular Conjugate- 
mediated Gene Transfer-In order to determine the effect of 
afiberAb#7 on gene transfer by adenovirus-linked molecular conju- 
gate complexes, ternary complexes containing adenovirus and human 
transferrin domains were prepared as described above. Adenovirus 
P202-Ad5 (2.5 X 10" particles) was incubated with 25 pg of either 
afiberAb#7 or PY203, or with an equal volume of HBS, for 30 min at 
room temperature prior to  the formation of the hTfpL/AdpL com- 
plexes. The antibody-treated complexes were then added to 60-mm 
HeLa plates. The cells were incubated, washed, and harvested as 
above. Results were also expressed as light units per 25 pg of total 
cellular protein. 
RESULTS 
Effect of afiberAb#7 on Binding and Internalization of 
Adenovirus-In order  to  determine  the effect of afiberAb#7 
on binding  and  internalization of adenovirus, 35S-labeled vi- 
rions were incubated with afiberAb#7 (10 pg of mAb/l.O x 
lolo particles)  prior  to delivery to  HeLa cells. Virions  labeled 
with  [35S]methionine were also incubated with an  irrelevant 
mAb, an  anti-influenza  neuraminidase  antibody (PY203), as 
a  control. The  results of these two assays  are  shown  in Fig. 1. 
To determine  the degree of 35S-labeled virion attachment  to 
cell surfaces, counts per minute (cpm) of radiation were 
analyzed. The  binding  study  indicates  that when  virions were 
ollherAhtf7 P Y X 3  
al1berAht7 PY2D3 
FIG. 1. Effect  of  afiberAb#7  on  binding ( A )  and  internali- 
zation ( B )  of adenovirus  type 5. 35S-labeled adenovirus type 5 (2 
X lo5 cpm/mg) was preincubated with afiberAb#7 or control mAb, 
PY203 (10 pg  of  mAb/l.O X 10" particles) for 30 min at room 
temperature prior to delivery to HeLa cells. This amount of antibody 
represents a 10-fold excess of that amount required to completely 
neutralize adenoviral infection. Experiments were performed in trip- 
licate. In A, cells were incubated with antibody-coated virions for 60 
min at  4 "C. This allowed for binding without internalization of 
virions. The cells were then washed with ice-cold PBS, and cells with 
adherent virus were harvested with 0.1 N NaOH. Cell lysates were 
then analyzed by scintillation. In B, cells were incubated with anti- 
body-coated virions for 60 min at 37 "C, to allow for internalization 
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treated with afiberAb#7, their ability to bind to HeLa cells 
was significantly decreased when compared to virions that 
had been preincubated with PY203. In  the same manner, the 
internalization study indicates that the internalization of 
afiberAb#7-treated virions significantly decreased when com- 
pared to virions treated with PY203. Thus, by blocking ad- 
enoviral binding, virions were also unable to accomplish cel- 
lular internalization. This established that  the observed basis 
of antibody neutralization was blockade of adenoviral binding 
and  internalization in target cells. 
Effect of afiberAb#7 on Facilitation of Molecular  Conjugate- 
mediated Gene Transfer by Free Adenovirus-We  have pre- 
viously demonstrated that adenovirus can dramatically facil- 
itate  human transferrin-poly(L-lysine)-mediated gene trans- 
fer (9, 19). This derives from the fact that  the adenovirus is 
co-internalized with the conjugate and,  thus, adenovirus-me- 
diated endosome disruption allows cell vesicle escape of the 
conjugate. The effect of afiberAb#7-coated adenovirus on 
facilitation of molecular conjugate-mediated gene transfer in 
HeLa cells is shown in Fig. 2. When PY203 was preincubated 
with adenovirus and co-delivered with the  hTfpL. DNA com- 
plex, gene transfer efficiency  was unaltered when compared 
to complexes co-delivered with antibody-free virions. How- 
ever, when afiberAb#7-treated adenovirus and  hTfpL. DNA 
complexes were co-delivered to cells, gene transfer was re- 
duced by approximately 94%. Values for hTfpL + Ad and 
hTfpL + Ad + afiberAb#7 are significantly different ( p  < 
O.OOOl), while values for hTfpL + Ad and hTfpL + Ad + 
PY203 are  statistically the same ( p  > 0.05). Thus,  this con- 
firms that adenoviral entry  is  a prerequisite for viral facilita- 
tion of molecular conjugate-mediated gene transfer. 
Effect of afiberAb#7 on Adenovirus-linked Molecular Con- 
jugate-mediated Gene Transfer-Since the blocking antibody 
ablated the ability of free virus to facilitate molecular conju- 
gate-mediated gene transfer, we wondered whether ablation 
of binding in the linked configuration would nevertheless 
allow retention of the endosome disruption capacity of the 
virus. Whereas one might expect a difference in gene transfer 
based on the loss of one entry mechanism, the fact that 
transferrin receptors are found in excess in HeLa cells makes 
T 
hTlpL hTfpL  hTlpL hTipL 
i d  i d  i d  
+ + 
aAberAM7 PY203 
FIG. 2. Effect of afiberAb#7 on facilitation of molecular 
conjugate-mediated gene transfer by  free adenovirus. Adeno- 
virus P202-Ad5, preincubated with afiberAb#7 or PY203 (10 pg of 
mAb/l.O X 10'' particles), and hTfpL.DNA complexes were co- 
delivered to HeLa cells. The cells were then incubated for 60 min at 
4 "C to allow  for binding without internalization of hTfpL. DNA and 
free virions, and washed to remove any unbound conjugate and 
adenovirus. This was followed by incubation at 37 "C to allow for 
virus and conjugate uptake. After 16 h, cell lysates were standardized 
for protein content and analyzed for luciferase activity. Results  are 
expressed as light units per 25 pg of total cellular protein. Experi- 
ments were performed in triplicate. 
this difference insignificant. The effect of afiberAb#7 on 
adenovirus-linked molecular conjugate-mediated gene trans- 
fer is shown in Fig.  3.  Gene transfer for linked-complexes that 
were preincubated with PY203 was as efficient as that ob- 
served for antibody-free linked-complexes. When linked com- 
plexes were then preincubated with afiberAb#7, gene transfer 
was also as efficient as previously observed. Values  for hTfpL/ 
AdpL, hTfpL/AdpL + afiberAb#7, and hTfpL/AdpL + 
PY203 are  statistically the same ( p  > 0.05). Since the virions 
that were part of the complex lacked the ability to  bind to 
their receptor, this result implied that hTfpL/AdpL.DNA 
complexes internalize only by an alternate non-adenoviral 
pathway. The binding-incompetent virions were nonetheless 
able to mediate vesicle disruption after internalization. In 
addition, adenovirus incubated with afiberAb#7 at pH 6.0 
prior to addition to cells was unable to  efficiently enter cells 
via the receptor-mediated endocytosis pathway (data not 
shown).  This  result indicates that  the monoclonal antibody 
remains bound to  the virion at  the  pH of endosome vesicles 
and, thus, the fiber protein is not free to participate in 
endosome lysis. This result is consistent with the concept 
that adenoviral binding and vesicle disruption  are  not  func- 
tionally linked. It is also consistent with our previous finding 
that hTfpL/AdpL.DNA complexes may function with high 
efficiency in gene transfer to erythroid cells, such as the K562 
cell line, which have a very small number of adenovirus 
receptors (11). 
DISCUSSION 
Multi-functional molecular conjugates may be constructed 
that are capable of high  efficiency  gene transfer (10,ll). They 
possess both specific and efficient internalization  and endo- 
some lysis mechanisms. When the ligand domain of the 
conjugate is  recognized by the appropriate cell surface recep- 
tor,  the molecular conjugate-DNA complex  is internalized by 
the receptor-mediated endocytosis pathway. To  prevent en- 
dosome-internalized DNA from being trapped within the cell 
vesicle, we have incorporated adenovirus, which mediates 
endosome disruption,  into the conjugate design. However, in 
doing so, the potential for cell specific targeting is undermined 
since in this configuration, the conjugate can bind by either 
the ligand domain or the adenovirus. Thus, we sought to 
ablate adenoviral binding by treating the conjugate with a 
neutralizing monoclonal anti-fiber antibody. 
hTlpL hTlpUAdpL hTlpUAdpL hTlpUAdpl 
allberAMt7 PY203 
FIG. 3. Effect of afiberAb#7 on adenovirus-linked molecu- 
lar conjugate-mediated gene transfer. Adenovirus P202-Ad5 was 
preincubated with afiberAb#7 or PY203 prior to formation of the 
hTfpL/AdpL.DNA complexes (10 pg of mAb/l.O X 10' particles). 
The hTfpL/AdpL. DNA complexes were then delivered to HeLa cells 
and incubated for 60 min at 4 "C to allow for binding of the complexes. 
Cells were washed and harvested as described in Fig. 2. Results are 
reported as light units per 25 pg of total protein.  Experiments were 
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FIG. 4. Multi-functional molecular conjugate vector that 
exploits adenovirus-mediated endosome lysis in a selective 
manner. Adenovirus is rendered binding-incompetent by interaction 
with a monoclonal anti-fiber antibody. The complex  will thus  enter 
cells by non-adenoviral pathways with virus serving exclusively as  an 
endosome lysis agent. 
We wondered whether blockade of adenoviral  binding 
would impede the  endosome lysis activity of the virus. In  this 
regard, we considered what  is known of the  adenoviral  entry 
pathway. At pH 7, the adenovirus fiber first binds to an 
uncharacterized receptor on the cell surface. The virion is 
then engulfed by a clathrin-coated  pit  and  internalized  into 
an endosome. After internalization, acidification of the  en- 
dosome results in  endosome disruption, allowing the virion to 
proceed to the nucleus to complete its life cycle (13). The 
exact  mechanism of endosome disruption  has  not  been  com- 
pletely delineated. However, monoclonal antibodies against 
the penton protein have been shown to selectively block 
endosome lysis (15). Thus, the penton base and/or peri- 
pentonal  capsid  components  appear  to be the crucial capsid 
proteins involved in  endosome  disruption.  Based  on  this, we 
hypothesized that we could block adenoviral  binding with an 
anti-fiber  antibody  without  disrupting endosome  lysis activ- 
ity. 
The  results  reported  here show that  it  is possible to  con- 
struct  multi-functional molecular conjugates  that  are  able  to 
mediate high efficiency gene transfer without having the 
adenovirus act as a competing ligand by using neutralizing 
amounts of an  anti-fiber  antibody.  This  is  depicted in Fig. 4. 
While  this  maneuver  can  eliminate  adenoviral binding, other 
possible sources of nonspecific binding may arise from the 
conjugate’s  design. For instance,  it  is known that polylysine 
can  bind nonspecifically to  certain cell lines (20). However, 
specific maneuvers may also be employed to address this 
nonspecificity  where relevant (21). In  this way, the specificity 
of the  conjugate  ligand  domain may be preserved. We have 
also shown that it is possible to preserve endosome lysis 
activity  in  the  absence of adenoviral  binding. These findings 
demonstrate  that  in  the process of adenoviral entry,  binding 
and endosome disruption  are  not  functionally linked. 
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